Latest From Zogenix Inc.
Neurocrine plans to advance XEN901 into Phase II in a rare pediatric epilepsy indication while eyeing opportunity in adult focal epilepsy. Xenon increases its runway to develop a pair of mid-stage epilepsy drugs.
GSK hopes the San Francisco biotech’s technology can help its cell therapy pipeline address solid tumors. Avacta partners with ADC on antibody-drug conjugates.
Keeping Track: Intercept Submits OCA For NASH; Zogenix’ Fintepla Returns; US FDA Approves Bavarian Nordic Vaccine
The latest drug development news and highlights from our US FDA Performance Tracker
GW Pharmaceuticals is pressing on with plans to launch its epilepsy treatment Epidyolex in the EU, starting with France and Germany.
- Specialty Pharmaceuticals
- Therapeutic Areas
- Neurology, Nervous System
- SJ2 Therapeutics Inc.
- North America
- Parent & Subsidiaries
- Zogenix Inc.
- Senior Management
Stephen J Farr, PhD, Pres. & CEO
Michael P Smith, EVP, CFO, Treasurer & Secretary
Bradley S Galer, MD, EVP, CMO
Gail M Farfel, PhD, EVP, Chief Dev. Officer
Ashish Sagrolikar, EVP, Chief Commercial Officer
- Contact Info
Phone: (858) 259-1165
5858 Horton St.
Emeryville, CA 94608
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.